Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Circulation|November 25, 2016
Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial HypertensionChristopher J Rhodes, Pavandeep Ghataorhe, John Wharton, et al.
The New England Journal of Medicine|September 30, 2025
Sotatercept for Pulmonary Arterial Hypertension within the First Year after DiagnosisVallerie V McLaughlin, Marius M Hoeper, David B Badesch, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 14, 2017
Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension RegistrySasiharan Sithamparanathan, Arun Nair, Logan Thirugnanasothy, et al.
Plos One|July 3, 2014
Risk factors for death in 632 patients with sickle cell disease in the United States and United KingdomMark T Gladwin, Robyn J Barst, J Simon R Gibbs, et al.
Circulation|September 9, 2011
Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United KingdomVandana Sachdev, Gregory J Kato, J Simon R Gibbs, et al.
Chest|February 13, 2021
Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)Carmine Dario Vizza, Marius M Hoeper, Doerte Huscher, et al.
The New England Journal of Medicine|April 1, 2025
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for DeathMarc Humbert, Vallerie V McLaughlin, David B Badesch, et al.
Blood|April 30, 2011
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacityRoberto F Machado, Robyn J Barst, Nancy A Yovetich, et al.
The Lancet. Respiratory Medicine|March 27, 2021
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialMarius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, et al.
Circulation|October 2, 2013
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)Karen M Olsson, Marion Delcroix, H Ardeschir Ghofrani, et al.
Pageof 12